Document Detail


Clinical and Immunologic Factors Associated With Bullous Pemphigoid Relapse During the First Year of Treatment: A Multicenter, Prospective Study.
MedLine Citation:
PMID:  24226428     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
IMPORTANCE Although predisposing factors for bullous pemphigoid (BP) have been recently established, no clinical or immunologic factors have yet been identified to predict disease outcome. OBJECTIVE To identify risk factors for BP relapse during the first year of treatment. DESIGN, SETTING, AND PARTICIPANTS Multicenter prospective study of 120 consecutive patients with newly diagnosed BP in 8 French dermatology departments. Baseline and 6 follow-up visits were planned to record disease activity and collect blood samples for measurement of serum anti-BP180 and anti-BP230 levels by means of enzyme-linked immunosorbent assay (ELISA). MAIN OUTCOMES AND MEASURES The end point was clinical relapse within the first year of therapy. Associations of clinical and immunologic (including serum levels of anti-BP180 and anti-BP230 autoantibodies) parameters with clinical relapse were assessed using univariate and multivariate analyses. RESULTS During the 1-year follow-up, 35 patients (29.2%) experienced relapse, whereas anti-BP180 and anti-BP230 ELISA results were similar at baseline between patients who did and did not experience relapse. Factors at baseline independently associated with relapse were extensive disease at inclusion (hazard ratio [HR], 2.37 [95% CI, 1.2-4.8]) and an associated dementia (HR, 2.09 [95% CI, 1.0-4.2]). Use of superpotent topical corticosteroids alone (by 100 patients [83.3%]) induced a dramatic, early decrease in serum levels of anti-BP180 and anti-BP230 autoantibodies. Mean early decreases in autoantibody levels between baseline and day 60 were lower in patients with relapse compared with patients with ongoing remission (-10.0% and -45.2%, respectively, for anti-BP180 levels [P < .001] and -11.8% and -35.4%, respectively, for anti-BP230 levels [P = .046]). A higher serum level of anti-BP180 at day 150, with a cutoff of 23 U/mL, provided 84.2% sensitivity, 44.8% specificity, 33.3% positive predictive value, and 89.7% negative predictive value for the occurrence of relapses between days 150 and 360. CONCLUSIONS AND RELEVANCE The pronounced decrease in the level of anti-BP180 autoantibodies and, to a lesser extent, those directed against BP230 confirmed the use of superpotent topical corticosteroids alone as a reference BP treatment. Furthermore, our study suggests that neurological diseases play a major role in BP, not only as a predisposing but also as a prognostic factor.
Authors:
Fanny Fichel; Coralie Barbe; Pascal Joly; Christophe Bedane; Pierre Vabres; François Truchetet; François Aubin; Catherine Michel; Juliette Jegou; Florent Grange; Frank Antonicelli; Philippe Bernard
Related Documents :
23681238 - Spontaneous cerebrospinal fluid otorrhea and rhinorrhea in idiopathic intracranial hype...
23481408 - Cytomegalovirus disease in nonimmunocompromised, human immunodeficiency virus-negative ...
24521848 - Case series of lower-extremity chronic wounds managed with an antibacterial foam dressi...
22935958 - The influence of haemodialysis on haemodynamic measurements using transpulmonary thermo...
4032128 - The gastro-duodenal epithelium in peptic ulceration.
8719508 - Dizziness of suspected cervical origin distinguished by posturographic assessment of hu...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-11-13
Journal Detail:
Title:  JAMA dermatology (Chicago, Ill.)     Volume:  -     ISSN:  2168-6084     ISO Abbreviation:  JAMA Dermatol     Publication Date:  2013 Nov 
Date Detail:
Created Date:  2013-11-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101589530     Medline TA:  JAMA Dermatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Dermatology, Reims University Hospital, University of Champagne-Ardenne, Reims, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Allogeneic Bone Marrow Mesenchymal Stem Cell Transplantation for Periodontal Regeneration.
Next Document:  Meristem transformation of sunflower via Agrobacterium.